Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Inducible T cell costimulatory ligand (ICOSL) is a type I transmembrane protein that serves as the exclusive ligand for the inducible T cell costimulator (ICOS), a receptor expressed on activated T cells. ICOSL is a member of the B7 family of immune regulatory molecules and plays an essential role in modulating adaptive immune responses by providing critical costimulatory signals necessary for full T cell activation and function.
The interaction between ICOS on activated T cells and ICOSL on APCs provides a crucial "second signal" required for optimal activation of naive T cells beyond antigen recognition through the TCR/CD3 complex. Blockade of this pathway can ameliorate disease progression by reducing inflammation-driven tissue damage mediated by aberrant Th1/Th2 responses or pathogenic autoantibody production from B-cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inducible T Cell Costimulatory Ligand (ICOSL).